Atlas Trials

Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors

Clinical trial NCT05660421 · WITHDRAWN

Trial details

NCT number
NCT05660421
Sponsor
Douglas Johnson
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid Neoplasm
Start date
2023-03-03
Primary completion
2025-04-03
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.